Literature DB >> 15233562

Adrenal tumors: how to establish malignancy ?

M Fassnacht1, W Kenn, B Allolio.   

Abstract

Discerning malignancy in adrenal tumors largely influences disease management and is, therefore, of utmost importance to both patient and physician. Clinical presentation (e.g. virilization) and baseline hormonal evaluation (e.g. high serum DHEAS) are occasionally of great value but usually provide only limited help in predicting malignancy. The probability of malignancy is clearly related to tumor size, as almost all lesions <3 cm are benign whereas a diameter of >6 cm indicates a high risk of malignancy. Computed tomography (CT) and magnetic resonance imaging (MRI) both contribute significantly to the characterization of adrenal masses. If the attenuation of a homogeneous mass with smooth border is 10 Hounsfield units or less in unenhanced CT the diagnosis of a lipid rich adenoma is established. Similarly, enhancement washout of more than 50% in CT at 10-15 min suggests a benign lesion. In MRI both rapid contrast enhancement after gadolinium followed by rapid washout and signal intensity loss using opposed-phase image in chemical shift analysis also indicate the presence of an adenoma. In contrast, adrenal carcinomas--but also pheochromocytomas--typically present as inhomogeneous lesion with intermediate-to-high intensity on T2 images in MRI. Margins and enhancement after contrast media in CT are irregular in adrenal carcinoma. Other imaging techniques either offer little additional information (NP-59 scintigraphy) or have not yet been fully established (positron emission tomography). Fine needle aspiration/cut biopsy is at present restricted to patients with a known extra-adrenal malignancy and suspected adrenal metastasis as the only evidence of disseminated disease. Adrenal tumors classified as benign undergo follow-up imaging to assess tumor growth. If an increase in diameter of >1 cm is seen, surgical removal is recommended. Even after tumor removal the diagnosis of dignity may remain difficult. Diagnostic scores together with new immunohistological markers are the methods of choice to assess malignancy. In conclusion, an interdisciplinary approach with a structured use of available diagnostic tools is needed to classify adrenal tumors correctly.

Entities:  

Mesh:

Year:  2004        PMID: 15233562     DOI: 10.1007/BF03351068

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  105 in total

1.  A study of the adrenal status in hypertension.

Authors:  A H SHAMMA; J W GODDARD; S C SOMMERS
Journal:  J Chronic Dis       Date:  1958-11

2.  Fine-needle aspiration cytology of adrenal masses in noncancer patients: clinicoradiologic and histologic correlations in functioning and nonfunctioning tumors.

Authors:  F Lumachi; S Borsato; A A Brandes; P Boccagni; A Tregnaghi; F Angelini; G Favia
Journal:  Cancer       Date:  2001-10-25       Impact factor: 6.860

3.  Adenomas of the adrenal cortex.

Authors:  R R COMMONS; C P CALLAWAY
Journal:  Arch Intern Med (Chic)       Date:  1948-01

4.  Adrenal masses in oncologic patients: functional and morphologic evaluation.

Authors:  I R Francis; A Smid; M D Gross; B Shapiro; B Naylor; G M Glazer
Journal:  Radiology       Date:  1988-02       Impact factor: 11.105

5.  On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes.

Authors:  H Hedeland; G Ostberg; B Hökfelt
Journal:  Acta Med Scand       Date:  1968-09

6.  FDG-PET in adrenocortical carcinoma.

Authors:  A Becherer; H Vierhapper; C Pötzi; G Karanikas; A Kurtaran; J Schmaljohann; A Staudenherz; R Dudczak; K Kletter
Journal:  Cancer Biother Radiopharm       Date:  2001-08       Impact factor: 3.099

7.  A re-evaluation of dopamine excretion in phaeochromocytoma.

Authors:  P A Tippett; A J McEwan; D M Ackery
Journal:  Clin Endocrinol (Oxf)       Date:  1986-10       Impact factor: 3.478

8.  The value of plasma markers for the clinical behaviour of phaeochromocytomas.

Authors:  E van der Harst; W W de Herder; R R de Krijger; H A Bruining; H J Bonjer; S W J Lamberts; A H van den Meiracker; T H Stijnen; F Boomsma
Journal:  Eur J Endocrinol       Date:  2002-07       Impact factor: 6.664

9.  Incidentally discovered adrenal tumors: an institutional perspective.

Authors:  M F Herrera; C S Grant; J A van Heerden; P F Sheedy; D M Ilstrup
Journal:  Surgery       Date:  1991-12       Impact factor: 3.982

10.  MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors.

Authors:  J H Bilbey; R F McLoughlin; P S Kurkjian; G E Wilkins; N H Chan; N Schmidt; J Singer
Journal:  AJR Am J Roentgenol       Date:  1995-03       Impact factor: 3.959

View more
  29 in total

1.  Determinants for malignancy in surgically treated adrenal lesions.

Authors:  Lucie Wright; Erik Nordenström; Martin Almquist
Journal:  Langenbecks Arch Surg       Date:  2011-09-21       Impact factor: 3.445

2.  Fine-needle aspiration cytology of adrenal masses: a re-assessment with histological confirmation.

Authors:  G Tirabassi; B Kola; M Ferretti; R Papa; T Mancini; F Mantero; M Scarpelli; M Boscaro; G Arnaldi
Journal:  J Endocrinol Invest       Date:  2011-10-04       Impact factor: 4.256

3.  [Adrenal tumors. Principles of diagnostics and operative treatment].

Authors:  A Gonsior; H Pfeiffer; D Führer; E Liatsikos; T Schwalenberg; J-U Stolzenburg
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

Review 4.  Multi-organ resection for locally advanced adrenocortical cancer: surgical strategy and literature review.

Authors:  F Guida; M Clemente; L Valvano; C Napolitano
Journal:  G Chir       Date:  2015 Sep-Oct

5.  Long-term outcome following laparoscopic adrenalectomy for large solid adrenal cortex tumors.

Authors:  F Fausto Palazzo; Frederic Sebag; Mauricio Sierra; Giuseppe Ippolito; Philippe Souteyrand; Jean-François Henry
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

Review 6.  Contemporary adrenal scintigraphy.

Authors:  Milton D Gross; Anca Avram; Lorraine M Fig; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-25       Impact factor: 9.236

7.  Sectional anatomy of the adrenal gland in the coronal plane.

Authors:  Gang Ma; Shu Wei Liu; Zhen Mei Zhao; Xiang Tao Lin; Li Lou; Zhen Ping Li; Yu Chun Tang; Shi Zhen Zhong
Journal:  Surg Radiol Anat       Date:  2008-02-02       Impact factor: 1.246

8.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

9.  Adrenal incidentaloma in pregnancy: clinical, molecular and immunohistochemical findings.

Authors:  F Fallo; V Pezzi; N Sonino; G Altavilla; L Barzon
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

10.  Spontaneous rupture of a functioning adrenocortical carcinoma.

Authors:  Jin Ook Chung; Dong Hyeok Cho; Jae Hyuk Lee; Dong Deuk Kwon; Dong Jin Chung; Min Young Chung
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.